PDCD1 and melanoma: To solve this clinically relevant issue, we performed ad hoc analyses to developed risk models to predict the progression-free survival (PFS), overall survival (OS), and response, respectively, based on the clinicodemographical characteristics and already available pre- and early-on treatment routinely tested laboratory parameters from the pooled data of two clinical trials testing anti-PD-1 monotherapies in advanced melanoma patients in China to facilitate future patient screening and clinical therapeutic decision making.